Medicare AdvantageCoverageMedium impact
MA08.132d, Margetuximab-cmkb (Margenza)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
May 28, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.132d for Margetuximab-cmkb (Margenza) has been reissued with an effective date of May 28, 2025. This is a pharmacy policy update that may affect coverage or billing requirements for this oncology medication.
Action Required
By May 28, 2025: Review the complete policy document at the provided URL to understand specific changes to Margetuximab-cmkb (Margenza) coverage requirements. Update billing procedures and prior authorization workflows as needed based on the detailed policy content.